Literature DB >> 32627634

Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia.

Colin D Godwin1,2, Olivia M Bates1, Sae Rin Jean3, George S Laszlo1, Eliotte E Garling1, Mary E Beddoe1, Michael H Cardone3, Roland B Walter1,2,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32627634      PMCID： PMC7686042          DOI： 10.1080/10428194.2020.1786553

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.

Authors:  Michael Certo; Victoria Del Gaizo Moore; Mari Nishino; Guo Wei; Stanley Korsmeyer; Scott A Armstrong; Anthony Letai
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

Review 2.  Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.

Authors:  Joseph Wynne; David Wright; Wendy Stock
Journal:  Blood Adv       Date:  2019-01-08

3.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

4.  Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line.

Authors:  Maurizio Cianfriglia; Alessandra Mallano; Alessandro Ascione; Maria Luisa Dupuis
Journal:  Int J Oncol       Date:  2010-06       Impact factor: 5.650

5.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 6.  Gemtuzumab ozogamicin in acute myeloid leukemia.

Authors:  C D Godwin; R P Gale; R B Walter
Journal:  Leukemia       Date:  2017-06-13       Impact factor: 11.528

7.  The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin.

Authors:  Roland B Walter; Brian W Raden; Michelle R Cronk; Irwin D Bernstein; Frederick R Appelbaum; Deborah E Banker
Journal:  Blood       Date:  2004-02-12       Impact factor: 22.113

8.  Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.

Authors:  George S Laszlo; Kimberly H Harrington; Chelsea J Gudgeon; Mary E Beddoe; Matthew P Fitzgibbon; Rhonda E Ries; Jatinder K Lamba; Martin W McIntosh; Soheil Meshinchi; Roland B Walter
Journal:  Oncotarget       Date:  2016-07-12

9.  Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.

Authors:  Donia M Moujalled; Giovanna Pomilio; Corina Ghiurau; Adam Ivey; Jessica Salmon; Sewa Rijal; Sarah Macraild; Lan Zhang; Tse-Chieh Teh; Ing-Soo Tiong; Ping Lan; Maia Chanrion; Audrey Claperon; Francesca Rocchetti; Adrien Zichi; Laurence Kraus-Berthier; Youzhen Wang; Ensar Halilovic; Erick Morris; Frédéric Colland; David Segal; David Huang; Andrew W Roberts; Ana Leticia Maragno; Guillaume Lessene; Olivier Geneste; Andrew H Wei
Journal:  Leukemia       Date:  2018-09-10       Impact factor: 11.528

10.  Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells.

Authors:  Glenna Wink Foight; Jeremy A Ryan; Stefano V Gullá; Anthony Letai; Amy E Keating
Journal:  ACS Chem Biol       Date:  2014-07-23       Impact factor: 5.100
View more
  3 in total

1.  A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.

Authors:  Mohammed O Gbadamosi; Vivek M Shastri; Abdelrahman H Elsayed; Rhonda Ries; Oluwaseyi Olabige; Nam H K Nguyen; Angelica De Jesus; Yi-Cheng Wang; Alice Dang; Betsy A Hirsch; Todd A Alonzo; Alan Gamis; Soheil Meshinchi; Jatinder K Lamba
Journal:  Leukemia       Date:  2022-06-10       Impact factor: 12.883

2.  Ganoderma lucidum Spore Polysaccharide Inhibits the Growth of Hepatocellular Carcinoma Cells by Altering Macrophage Polarity and Induction of Apoptosis.

Authors:  Ming Song; Zhen-Hao Li; Hong-Shun Gu; Ru-Ying Tang; Rui Zhang; Ying-Li Zhu; Jin-Lian Liu; Jian-Jun Zhang; Lin-Yuan Wang
Journal:  J Immunol Res       Date:  2021-03-05       Impact factor: 4.818

3.  Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.

Authors:  Edoardo Pennesi; Naomi Michels; Erica Brivio; Vincent H J van der Velden; Yilin Jiang; Adriana Thano; Anneke J C Ammerlaan; Judith M Boer; H Berna Beverloo; Barbara Sleight; Ying Chen; Britta Vormoor-Bürger; Susana Rives; Bella Bielorai; Claudia Rössig; Arnaud Petit; Carmelo Rizzari; Gernot Engstler; Jan Starý; Francisco J Bautista Sirvent; Christiane Chen-Santel; Benedicte Bruno; Yves Bertrand; Fanny Rialland; Geneviève Plat; Dirk Reinhardt; Luciana Vinti; Arend Von Stackelberg; Franco Locatelli; Christian M Zwaan
Journal:  Leukemia       Date:  2022-04-25       Impact factor: 12.883
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.